Rockville, Md. – Abt Associates will continue its work to reduce tuberculosis (TB) cases in Uzbekistan through a new five-year award from the U.S. Agency for International Development. The $18 million TB Free Uzbekistan project will expand the scale and sustainability of approaches Abt has led in the country under its current regional USAID Eliminating Tuberculosis in Central Asia (ETICA) Program.
Through TB Free Uzbekistan, Abt will partner with the country’s National TB Program to strengthen the capacity of people and institutions; improve data availability, use, and system interoperability; and operationalize policies and guidelines. These joint interventions will optimize delivery of high-quality, people-centered services for all forms of TB and identify and address systemic impediments to improved TB outcomes.
While Uzbekistan has made great strides in TB control, the country still ranks in the top 30 globally for its multidrug-resistant TB burden. Since 2019, ETICA has exceeded project targets for drug-resistant TB cases diagnosed and started on second-line drugs.
“We’re honored to build on ETICA’s successes through TB Free Uzbekistan,” said Mariandrea Chamorro, vice president of Abt’s Global Development Delivery Practice. “More significantly, this new program will help strengthen a more resilient and sustainable TB health system to address the main social drivers of this epidemic.”
The Abt team includes Uzbek partner Soglom Avlod and international partners BAO Systems and IML Red.
About Abt Associates
Abt Associates is a global consulting and research firm that combines data and bold thinking to improve the quality of people's lives. We partner with clients and communities to advance equity and innovation—from creating scalable digital solutions and combatting infectious disease, to mitigating climate change and evaluating programs for measurable social impact. https://www.abtassociates.com